Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 106 AL 120

Covalent small-molecule RNA targeting in Alzheimer's disease: Computational strategies, challenges and opportunities

Kumar V, Arulsamy S, Sharma S, Kumar S, Kakoty V.

Drug Discov Today. 2026 Sep;31(5):104758. doi: 10.1016/j.drudis.2026.104758. Epub 2026 Aug 4.

Aluminum and Alzheimer's disease in the 21st century: An umbrella review of evidence and controversies

Domingo JL, Colomina MT.

Neurotoxicology. 2026 Sep;116:103531. doi: 10.1016/j.neuro.2026.103531. Epub 2026 Jul 24.

Frailty as an underrepresented dimension in clinical trials of Alzheimer's disease therapies

Solfrizzi V, Imbimbo BP.

J Alzheimers Dis. 2026 Sep;113(1):83-88. doi: 10.1177/13872877261466693. Epub 2026 Jul 9.

Characterising patients with Alzheimer's disease in England: a cohort study using data from Clinical Practice Research Datalink linked to Hospital Episode Statistics

Afonso AS, Schroeder KM, Mitchell L, Carragher N, Casey C, Patel N.

BMJ Open. 2026 Aug 28;16(8):e115438. doi: 10.1136/bmjopen-2025-115438.

Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

Sharma A, Suresh V, Kola PR, Raj R, Javairia F, Nithyanandam A, Kaur A, Arora H, Uwishema O, Gorty D, Beriwal N, Verma A, Qidwai K, Singh Malhotra H, Kumar Garg R.

J Alzheimers Dis. 2026 Sep;113(1):65-82. doi: 10.1177/13872877261466097. Epub 2026 Jul 11.

Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer's disease

Sánchez Valle R, Lleó Bisa A, Villarejo Galende A, Cuartero Rodríguez E, Escudero-Torrella J, Bargallo Alabart N.

J Prev Alzheimers Dis. 2026 Aug;13(7):100586. doi: 10.1016/j.tjpad.2026.100586. Epub 2026 May 5.

Metal-based nanoparticles' potential in Alzheimer's disease diagnosis, therapy and theranostics

Khorrami S, Alifarsangi A, Mohammed LJ, Amshawee AM, Zarrabi A.

Nanoscale. 2026 Sep 17;18(35):18670-18694. doi: 10.1039/d5nr04613k.

Stage-Dependent Cognitive Effects of a Multinutrient Intervention in Alzheimer's Disease: A Stage-Stratified Meta-Analysis

Han P, Dong P, Zhou Y, Zhang L, Mahomed O.

J Vis Exp. 2026 Sep 1;(235). doi: 10.3791/72385.

[Antibody therapy in Alzheimer's disease]

Schnieder M.

Z Gerontol Geriatr. 2026 Oct;59(6):522-530. doi: 10.1007/s00391-026-02640-8. Epub 2026 Sep 9.

Amyloid-Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in Alzheimer Disease

Greenberg SM, Iadecola C, Chou SH, Cogswell PM, Elkind MSV, Hicks WJ, Le C, Levine DA, Lipton R, Massimo L, Mohl SM, Seshadri S, Snyder HM, Yaffe K, Zachrison KS; ARIA Summit Working Group.

J Am Heart Assoc. 2026 Sep;15(17):e048108. doi: 10.1161/JAHA.125.048108. Epub 2026 Aug 20.

Auvelity (Dextromethorphan-Bupropion) for Agitation and Aggression in Alzheimer's Disease Dementia: Mechanism, Efficacy, Safety, and Clinical Considerations

Sarangal M, Sarangal C, Vora J, Soni K.

Psychopharmacol Bull. 2026 Sep 18;56(4 Suppl 1):82-87. doi: 10.64719/pb.20773.

Bacopa monnieri and Alzheimer's disease: mechanistic convergence, cognitive outcomes and translational perspectives

Kumawat A, Sharma MM, Nathani S.

Inflammopharmacology. 2026 Sep;34(9):6035-6057. doi: 10.1007/s10787-026-02369-1. Epub 2026 Aug 19.

Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease

Grossberg GT, Sabbagh MN, Chumki SR, Wang D, Such P, Zhang Z, Palma AM, Cummings JL.

J Geriatr Psychiatry Neurol. 2026 Sep;39(5):589-601. doi: 10.1177/08919887251407124. Epub 2025 Dec 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias